The Senate Finance Committee today held the first in a planned series of bipartisan hearings on high prescription drug prices and potential policy and oversight solutions to lower costs for patients. Witness Kathy Sego described her family’s struggle to afford insulin for her son, which costs them $487 per vial with insurance. Mark Miller, vice president of health care for the Laura and John Arnold Foundation and former executive director of the Medicare Payment Advisory Commission, discussed policy options to address rising drug costs in Medicare and Medicaid. Douglas Holtz-Eakin, president of the American Action Forum, called for promoting competition and financial incentives to keep costs and prices down. Peter Bach, a physician who leads the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center in New York, said most participants in the pharmaceutical supply chain benefit from rising spending and prices due to “inflationary distortions” in the system. Chairman Chuck Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Ore., said they plan to bring drug company executives before the panel in the future.

The House Committee on Oversight and Reform also held a hearing today on the issue. Witnesses included representatives from AARP, the Program on Regulation, Therapeutics and Law at Harvard Medical School, and Johns Hopkins University’s Bloomberg School of Public Health.

The AHA, Federation of American Hospitals and American Society of Health-System Pharmacists earlier this month released a report that found continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and staffing investments and identify alternative therapies. To restrain out-of-control drug prices, the AHA has recommended several options including stopping brand-name manufacturers' anticompetitive actions by addressing ever-greening and pay-for-delay practices, speeding up generic drug approvals, and passing the CREATES Act.

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Congress last night approved legislation providing discretionary funding for certain federal programs for fiscal year 2019, preventing a shutdown of those…
Headline
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing…
Blog
Earlier this month AHA released a blog post that pointed out numerous flaws in a recent Health Affairs study on hospital and physician prices between 2007 and…
Headline
The AHA and Federation of American Hospitals today urged the U.S. Supreme Court to review a federal appeals court decision that allows False Claims Act…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on legislation to roll back changes to the Affordable Care Act by the Trump…